In A Big Trial, The Weight Loss Medication Wegovy Reduced The Risk Of Heart Attack.
In A Big Trial, The Weight Loss Medication Wegovy Reduced The Risk Of Heart Attack. Doctors in a large audience at the recent American Heart Association congress broke into spontaneous applause. A. Michael Lincoff, a cardiologist at Cleveland Clinic, has just revealed the startling and occasionally puzzling findings of a brand-new clinical experiment involving the weight loss medication semaglutide. Lincoff announced on November 11 that the weight loss medication, marketed under the brand name Wegovy, reduced patients’ risk of serious cardiovascular issues by 20 percent. Additionally, during the course of the study’s 40 months or so, on average, it decreased the patients’ probability of dying, regardless of the cause. Thanks to Lincoff’s findings, semaglutide—which is now used by doctors to treat obesity and diabetes—has yet another function. An advantage for the cardiovascular system has already been found in type 2 diabetics by earlier research. This new study is the first to demonst...